Announcements

OBI in-licensed “anti-Trop2 antibody” exclusive rights from Biosion

1.Date of occurrence of the event: 2021/12/08 2.Counterparty to the contract or commitment: Biosion, Inc. 3.Relationship with the Company: None 4.Starting and ending dates (or rescission date) of the contract …

The Active Cancer Immunotherapy OBI-822, has been granted by COFEPRIS of Mexico to proceed to Phase III Human Clinical Study

1.Date of occurrence of the event: 2021/12/03 2.New drug name or code: Active cancer immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication: OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. …

Announcement on behalf of subsidiary, OBIGEN, that OBI-858 completes its Phase I and demonstrates good safety, proceeding to Phase II as planned

1.Date of occurrence of the event:2021/11/30 2.New drug name or code:Novel Botulinum Neurotoxin, OBI-858 3.Indication:OBI-858, an in-house developed new botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. …

OBI’s BOD resolved to in-license a preclinical project from a biotech company specialized in novel cancer therapies

1.Date of occurrence of the event: 2021/11/26 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office 4.Reciprocal shareholding ratios: No applicable 5.Cause …

Announcement of the resolution of the Board of Directors of the Company to issue common shares through cash capital increase

1.Date of the board of directors resolution: 2021/11/26 2.Source of capital increase funds: Issue common shares through cash capital increase 3.Number of shares issued (not including those distributed to employees …

Supplementary statements on news article

1.Date of occurrence of the event: 2021/11/12 2.Company name: OBI Pharma Inc. 3.Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4.Reciprocal shareholding ratios: Not applicable 5.Name …

Intellectual property rights licensing of OBI’s cancer therapies in China has been granted by MOEAIC

1. Date of occurrence of the event: 2021/11/11 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding …

Announcement of amendment of the regulations for issuance and subscription of 2021 employee stock options

1.Date of occurrence of the event: 2021/11/05 2.Date of the original announcement and reporting: 2021/08/06 3.Summary of the content originally announced and reported: The Company originally resolved and announced the …

Announcement of the Consolidated Financial Statements for the third quarter of 2021 were authorized for issuance by the Board of Directors

1.Date of the financial reports submitted to the board of directors or approved by the board of directors: 2021/11/05 2.Date of the financial reports approved by the audit committee: 2021/11/05 …

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

1.Date of institutional investor conference: 2021/11/11 2.Time of institutional investor conference: 2021/11/11 3.Location of institutional investor conference: Masterlink Securities (Address:No.97-11, Sec. 2, Dunhua S. Rd., Da’an Dist., Taipei City 106, …